MicroRNA-136 promotes vascular muscle cell proliferation through the ERK1/2 pathway by targeting PPP2R2A in atherosclerosis

Current Vascular Pharmacology

Volumn 13, Issue 3, 2015, Pages 405-412

  Zhang, Chun Feng ^a   Kang, Kai ^a   Li, Xin Miao ^a   Xie, Bao Dong ^a  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; MicroRNA; MiR 136; Proliferation; Vascular smooth muscle cells

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; MICRORNA; MICRORNA 136; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B; UNCLASSIFIED DRUG; MIRN136 MICRORNA, HUMAN; PHOSPHOPROTEIN PHOSPHATASE 2; PLATELET DERIVED GROWTH FACTOR; PPP2R2A PROTEIN, HUMAN;

ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; UPREGULATION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING; BIOSYNTHESIS; CORONARY ARTERY DISEASE; CYTOLOGY; DRUG EFFECTS; GENE SILENCING; GENETICS; METABOLISM; PATHOLOGY; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION;

ATHEROSCLEROSIS; CELL PROLIFERATION; CORONARY ARTERY DISEASE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MAP KINASE SIGNALING SYSTEM; MICRORNAS; MUSCLE, SMOOTH, VASCULAR; PLATELET-DERIVED GROWTH FACTOR; PROTEIN BIOSYNTHESIS; PROTEIN PHOSPHATASE 2; SINCALIDE;

EID: 84937156651     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161112666141118094612     Document Type: Article

References (34)

1. [1] Aburto NJ, Hanson S, Gutierrez H, Hooper L, Elliott P, Cappuccio FP. Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses. BMJ 2013; 346: f1378.
2. [2] Rudijanto A. The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis. Acta Med Indones 2007; 39(2): 86-93.
3. [3] Marx SO, Totary-Jain H, Marks AR. Vascular smooth muscle cell proliferation in restenosis. Circ Cardiovasc Interv 2011; 4(1): 104-11.
4. [4] Dong LH, Wen JK, Miao SB, et al. Baicalin inhibits PDGF-BBstimulated vascular smooth muscle cell proliferation through suppressing PDGFRbeta-ERK signaling and increase in p27 accumulation and prevents injury-induced neointimal hyperplasia. Cell Res 2010; 20(11): 1252-62.
5. [5] Farazi TA, Spitzer JI, Morozov P, Tuschl T. miRNAs in human cancer. J Pathol 2011; 223(2): 102-15.
6. [6] Van Wynsberghe PM, Chan SP, Slack FJ, Pasquinelli AE. Analysis of microRNA expression and function. Methods Cell Biol 2011; 106: 219-52.
7. [7] Yates LA, Norbury CJ, Gilbert RJ. The long and short of microRNA. Cell 2013; 153(3): 516-9.
8. [8] Mo YY. MicroRNA regulatory networks and human disease. Cell Mol Life Sci 2012; 69(21): 3529-31.
9. [9] Albinsson S, Suarez Y, Skoura A, Offermanns S, Miano JM, Sessa WC. MicroRNAs are necessary for vascular smooth muscle growth, differentiation, and function. Arterioscler Thromb Vasc Biol 2010; 30(6): 1118-26.
10. [10] Elia L, Quintavalle M, Zhang J, et al. The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ 2009; 16(12): 1590-8.
11. [11] Yu J, Wang F, Yang GH, et al. Human microRNA clusters: genomic organization and expression profile in leukemia cell lines. Biochem Biophys Res Commun 2006; 349(1): 59-68.
12. [12] Lee DY, Jeyapalan Z, Fang L, et al. Expression of versican 3’-untranslated region modulates endogenous microRNA functions. PloS One 2010; 5(10): e13599.
13. [13] Shen S, Yue H, Li Y, et al. Upregulation of miR-136 in human non-small cell lung cancer cells promotes Erk1/2 activation by targeting PPP2R2A. Tumour Biol 2014; 35(1): 631-40.
14. [14] Stein JJ, Iwuchukwu C, Maier KG, Gahtan V. Thrombospondin-1-induced smooth muscle cell chemotaxis and proliferation are dependent on transforming growth factor-beta2 and hyaluronic acid synthase. Mol Cell Biochem 2013; 384(1-2): 181-6.
15. [15] Liu G, Hitomi H, Rahman A, et al. High sodium augments angiotensin II-induced vascular smooth muscle cell proliferation through the ERK 1/2-dependent pathway. Hypertens Res 2014; 37(1): 13-8.
16. [16] Rodriguez-Moyano M, Diaz I, Dionisio N, et al. Urotensin-II promotes vascular smooth muscle cell proliferation through storeoperated calcium entry and EGFR transactivation. Cardiovasc Res 2013; 100(2): 297-306.
17. [17] Tomankova T, Petrek M, Kriegova E. Involvement of microRNAs in physiological and pathological processes in the lung. Respir Res 2010; 11: 159.
18. [18] Zhang C. MicroRNAs in vascular biology and vascular disease. J Cardiovasc Transl Res 2010; 3(3): 235-40.
19. [19] Bonauer A, Boon RA, Dimmeler S. Vascular microRNAs. Curr Drug Targets 2010; 11(8): 943-9.
20. [20] Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biology. Nature 2011; 469(7330): 336-42.
21. [21] Li P, Zhu N, Yi B, et al. MicroRNA-663 regulates human vascular smooth muscle cell phenotypic switch and vascular neointimal formation. Circ Res 2013; 113(10): 1117-27.
22. [22] Najafi-Shoushtari SH. MicroRNAs in cardiometabolic disease. Curr Atheroscler Rep 2011; 13(3): 202-7.
23. [23] Li P, Liu Y, Yi B, et al. MicroRNA-638 is highly expressed in human vascular smooth muscle cells and inhibits PDGF-BBinduced cell proliferation and migration through targeting orphan nuclear receptor NOR1. Cardiovasc Res 2013; 99(1): 185-93.
24. [24] Yang Y, Wu J, Guan H, et al. MiR-136 promotes apoptosis of glioma cells by targeting AEG-1 and Bcl-2. FEBS Lett 2012; 586(20): 3608-12.
25. [25] Kurimchak A, Grana X. PP2A Counterbalances phosphorylation of pRB and mitotic proteins by multiple CDKs: potential implications for PP2A disruption in cancer. Genes Cancer 2012; 3(11-12): 739-48.
26. [26] Kalev P, Simicek M, Vazquez I, et al. Loss of PPP2R2A inhibits homologous recombination DNA repair and predicts tumor sensitivity to PARP inhibition. Cancer Res 2012; 72(24): 6414-24.
27. [27] Ouchida M, Kanzaki H, Ito S, et al. Novel direct targets of miR-19a identified in breast cancer cells by a quantitative proteomic approach. PloS One 2012; 7(8): e44095.
28. [28] Yan L, Guo S, Brault M, et al. The B55alpha-containing PP2A holoenzyme dephosphorylates FOXO1 in islet beta-cells under oxidative stress. Biochem J 2012; 444(2): 239-47.
29. [29] Cheng Y, Liu W, Kim ST, et al. Evaluation of PPP2R2A as a prostate cancer susceptibility gene: a comprehensive germline and somatic study. Cancer Genet 2011; 204(7): 375-81.
30. [30] Mosca L, Musto P, Todoerti K, et al. Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. Am J Hematol 2013; 88(1): 16-23.
31. [31] Yang R, Yang L, Qiu F, et al. Functional genetic polymorphisms in PP2A subunit genes confer increased risks of lung cancer in southern and eastern Chinese. PloS One 2013; 8(10): e77285.
32. [32] Kuo YC, Huang KY, Yang CH, Yang YS, Lee WY, Chiang CW. Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. J Biol Chem 2008; 283(4): 1882-92.
33. [33] O’Shaughnessy RF, Welti JC, Sully K, Byrne C. Akt-dependent Pp2a activity is required for epidermal barrier formation during late embryonic development. Development 2009; 136(20): 3423-31.
34. [34] Yu N, Kozlowski JM, Park, II, et al. Overexpression of transforming growth factor beta1 in malignant prostate cells is partly caused by a runaway of TGF-beta1 auto-induction mediated through a defective recruitment of protein phosphatase 2A by TGFbeta type I receptor. Urology 2010; 76(6): 1519 e8-13.